news.bms.com/press-release/bmy/bristol-myers-squibb-appoints-fouad-namouni-md-oncology-development-head

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that Fouad Namouni, M.D., has been appointed Oncology ...

scrip.pharmaintelligence.informa.com/SC098931/BMSs-Fouad-Namouni-On-The-Future-Of-ImmunoOncology

s Head of Oncology Fouad Namouni told Scrip on the sidelines of the 2017 American Society of Clinical Oncology (ASCO) annual meeting, held June 2-6 in  ...

www.comparably.com/companies/bristol-myers-squibb/fouad-namouni-m-d

Dr. Fouad Namouni, M.D. has been the Head of Oncology Development at Bristol -Myers Squibb Company since July 25, 2016. Dr. Namouni joined Bristol-Myers ...

www.fiercebiotech.com/biotech/bristol-myers-advances-new-lag-3-med-relatlimab-melanoma-to-fight-pd-1-resistance

Sep 12, 2017 ... ... cells, the response rate triples,” said Fouad Namouni, Bristol-Myers' head of ... “ Biomarkers is a major investment field for us,” Namouni said.

www.fiercepharma.com/pharma/asco-bristol-myers-racks-up-opdivo-combo-data-to-sell-its-new-biomarker-but-will-doctors-buy

Jun 4, 2018 ... The way BMS' oncology development head, Fouad Namouni, sees it, ... biomarker at the time of making treatment decisions,” Namouni said.

quotes.wsj.com/BMY/company-people

Fouad Namouni Head-Oncology Development. Louis S. Schmukler President- Global Manufacturing & Supply. Frederick Egenolf Director-Community Affairs & ...

www.businesswire.com/news/home/20180918005452/en/European-Medicines-Agency-Validates-Bristol-Myers-Squibb%E2%80%99s-Application

Sep 18, 2018 ... ... working closely with the EMA as they review this application,” said Fouad Namouni, M.D., head, oncology development, Bristol-Myers Squibb ...

www.reuters.com/article/us-bristol-myers-cancer-idUSKBN1751AY

Apr 3, 2017 ... “This level of survival rate at two years is really unprecedented,” said Fouad Namouni, Bristol's head of medical and oncology development.

endpts.com/following-cancer-combo-deal-with-bristol-myers-taris-gets-25m-series-b

Dec 21, 2017 ... Fouad Namouni. Yesterday, Taris and BMS announced their collaboration on a Phase Ib combo study for muscle invasive bladder cancer.